On 09 December 2020
The Board of Biocon Biologics (BBL) on 09 December 2020 has approved the allotment of 1,125 Unlisted, Unsecured, Redeemable, Optionally Convertible Debentures (OCDs) at face value of Rs. 1 crore each aggregating to Rs. 1,125 crore of BBL to the Investor i.e. Goldman Sachs India AIF Scheme - 1, a scheme setup under Goldman Sachs India Alternative Investment Trust, acting through its investment manager, Goldman Sachs (India) Alternative Investment Management.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
